Molibresib (I-BET-762)

別名: GSK525762, GSK525762A

目錄號：S7189 Purity: 99.87%

Molibresib (I-BET-762, GSK525762, GSK525762A) 是一種BET蛋白抑制劑，無細胞試驗中IC50約為35 nM，抑制巨噬細胞產生促炎性蛋白質，并抑制急性炎癥，對其他溴區(qū)結合域包含的蛋白具有高度選擇性。

Molibresib (I-BET-762) Chemical Structure

CAS: 1260907-17-2

規(guī)格	價格	庫存
10mM (1mL in DMSO)	2211.3	現(xiàn)貨
2mg	958.23	現(xiàn)貨
10mg	2858.31	現(xiàn)貨
50mg	7944.3	現(xiàn)貨
100mg	13678.17	現(xiàn)貨
1g	48895.1	現(xiàn)貨
更大包裝有超大折扣
400-668-6834 info@selleck.cn

產品質控

批次：純度： 99.87%

99.87

Molibresib (I-BET-762)相關產品

相關靶點	BET p300/CBP BRPF bromodomain	點擊展開
相關產品	ICG-001 Birabresib (OTX015) I-BET151 (GSK1210151A) SGC-CBP30 EED226 Apabetalone (RVX-208) KG-501 CPI-203 compound 3i (666-15) PFI-3 AZD5153 6-hydroxy-2-naphthoic acid PFI-1 (PF-6405761) Mivebresib (ABBV-075) ABBV-744 UNC1215 I-BRD9 Bromosporine PLX51107 GSK1324726A (I-BET726) Pelabresib (CPI-0610) PF-CBP1 HCl INCB054329 MS436 GSK2801 UNC669 MZ-1 NEO2734 OF-1 CPI-637 GSK6853 I-CBP112 BI-7273 PFI-4 INCB057643 GSK 5959 dBET57 BI-9564 Histone?Acetyltransferase?Inhibitor?II	點擊展開
相關化合物庫	激酶抑制劑庫 FDA藥物庫天然產物庫已知活性藥物庫-I 高選擇性抑制劑庫	點擊展開

細胞實驗數據示例

細胞系	實驗類型	給藥濃度	孵育時間	活性描述	文獻信息
TY82	Function assay	0.2 to 1 uM	24 hrs	Inhibition of BRD4 in human TY82 cells assessed as reduction in c-Myc protein expression at 0.2 to 1 uM after 24 hrs by Western blot analysis	29525435
TY82	Function assay	0.2 to 1 uM	24 hrs	Inhibition of BRD4 in human TY82 cells assessed as reduction in c-Myc mRNA expression at 0.2 to 1 uM after 24 hrs by RT-PCR analysis	29525435
TY82 or NCI-H1299	Function assay	0.2 to 1 uM	24 hrs	Inhibition of BRD4 in human TY82 or NCI-H1299 cells assessed as reduction in PD-L1 protein expression at 0.2 to 1 uM after 24 hrs by Western blot analysis	29525435
TY82 or NCI-H1299	Function assay	0.2 to 1 uM	24 hrs	Inhibition of BRD4 in human TY82 or NCI-H1299 cells assessed as reduction in PD-L1 mRNA expression at 0.2 to 1 uM after 24 hrs by RT-PCR analysis	29525435
HepG2	Function assay		18 hrs	Induction of human ApoA1 gene expression in stably transfected human HepG2 cells coexpressing luciferase reporter gene after 18 hrs by luminescence assay, EC50 = 0.7 μM.	21568322
HepG2	Function assay		6 hrs	Induction of human ApoA1 protein synthesis in human HepG2 cells assessed as neosynthesised radiolabeled protein secretion after 6 hrs by SDS PAGE analysis in presence of [35S]methionine	21568322
HepG2	Function assay		18 hrs	Upregulation of ApoA1 expression in human HepG2 cells assessed as concentration required to increase 70% of luciferase activity after 18 hrs by luciferase reporter gene assay, EC170 = 0.2 μM.	22386529
HepG2	Function assay		18 hrs	Induction of human ApoA1 gene expression in stably transfected human HepG2 cells coexpressing luciferase reporter gene after 18 hrs by luminescence assay, EC50 = 0.7 μM.	22924434
Raji	Function assay		4 hrs	Inhibition of BRD4 in human Raji cells assessed as reduction of MYC expression after 4 hrs, IC50 = 0.19 μM.	24900758
Rosetta2 DE3	Function assay		30 mins	Displacement of FAM-labeled ZBA248 from BRD3 BD2 (306 to 417 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.0303 μM.	26080064
Rosetta2 DE3	Function assay		30 mins	Displacement of FAM-labeled ZBA248 from BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.0323 μM.	26080064
Rosetta2 DE3	Function assay		30 mins	Displacement of FAM-labeled ZBA248 from BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.0388 μM.	26080064
Rosetta2 DE3	Function assay		30 mins	Displacement of FAM-labeled ZBA248 from BRD2 BD2 (349 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.0492 μM.	26080064
Rosetta2 DE3	Function assay		30 mins	Displacement of FAM-labeled ZBA248 from BRD3 BD1 (24 to 144 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.0539 μM.	26080064
Rosetta2 DE3	Function assay		30 mins	Displacement of FAM-labeled ZBA248 from BRD2 BD1 (72 to 205 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.0568 μM.	26080064
MV4-11	Cytotoxicity assay		4 days	Cytotoxicity against human MV4-11 cells harboring MLL1 fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay, IC50 = 0.093 μM.	26080064
Rosetta2 DE3	Function assay		30 mins	Displacement of FAM-labeled ZBA248 from BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, IC50 = 0.0984 μM.	26080064
Rosetta2 DE3	Function assay		30 mins	Displacement of FAM-labeled ZBA248 from BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, IC50 = 0.156 μM.	26080064
MOLM13	Cytotoxicity assay		4 days	Cytotoxicity against human MOLM13 cells harboring MLL1 fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay, IC50 = 0.241 μM.	26080064
Rosetta2 DE3	Function assay		30 mins	Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 2 (333 to 460 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay, Ki = 0.023 μM.	28463487
Rosetta2 DE3	Function assay		30 mins	Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay, Ki = 0.0464 μM.	28463487
Rosetta2 DE3	Function assay		30 mins	Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 2 (333 to 460 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay, IC50 = 0.0775 μM.	28463487
MV4-11	Growth inhibition assay		4 days	Growth inhibition of human MV4-11 cells after 4 days by WST-8 assay, IC50 = 0.093 μM.	28463487
Rosetta2 DE3	Function assay		30 mins	Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay, IC50 = 0.145 μM.	28463487
MOLM13	Growth inhibition assay		4 days	Growth inhibition of human MOLM13 cells after 4 days by WST-8 assay, IC50 = 0.241 μM.	28463487
TY82	Antiproliferative assay		72 hrs	Antiproliferative activity against human TY82 cells after 72 hrs by CCK8 assay, IC50 = 0.2 μM.	28586718
MM1S	Antiproliferative assay		72 hrs	Antiproliferative activity against human MM1S cells after 72 hrs by CCK8 assay, IC50 = 0.23 μM.	28586718
BL21 (DE3)-codon plus-RIL	Function assay		4 hrs	Inhibition of JQ1-FITC binding to His6-tagged BRD4-BD1 (unknown origin) expressed in Escherichia coli BL21 (DE3)-codon plus-RIL cells incubated in dark for 4 hrs by fluorescence anisotropy assay, IC50 = 0.26 μM.	28586718
NALM16	Cytotoxicity assay		5 days	Cytotoxicity against human NALM16 cells assessed as reduction in cell viability after 5 days by CellTiter-Glo assay, EC50 = 0.27 μM.	29170024
NALM6	Cytotoxicity assay		5 days	Cytotoxicity against human NALM6 cells assessed as reduction in cell viability after 5 days by CellTiter-Glo assay, EC50 = 0.39 μM.	29170024
697	Cytotoxicity assay		5 days	Cytotoxicity against human 697 cells assessed as reduction in cell viability after 5 days by CellTiter-Glo assay, EC50 = 1.17 μM.	29170024
HD-MB03	Cytotoxicity assay		5 days	Cytotoxicity against human HD-MB03 cells assessed as reduction in cell viability after 5 days by CellTiter-Glo assay, EC50 = 3.5 μM.	29170024
TY82	Antiproliferative assay		72 hrs	Antiproliferative activity against human TY82 cells after 72 hrs by CCK8 assay, IC50 = 0.3043 μM.	29525435
MM1S	Antiproliferative assay		72 hrs	Antiproliferative activity against human MM1S cells after 72 hrs by CCK8 assay, IC50 = 0.3492 μM.	29525435
C4-2B	Antiproliferative assay		96 hrs	Antiproliferative activity against human C4-2B cells after 96 hrs by Cell-Titer glo reagent based luminescence assay	29541371
22Rv1	Antiproliferative assay		96 hrs	Antiproliferative activity against human 22Rv1 cells after 96 hrs by Cell-Titer glo reagent based luminescence assay	29541371
LNCAP	Antiproliferative assay		96 hrs	Antiproliferative activity against human LNCAP cells after 96 hrs by Cell-Titer glo reagent based luminescence assay	29541371
MV411	Cytotoxicity assay		72 hrs	Cytotoxicity against human MV411 cells after 72 hrs by CellTiter-Glo assay, IC50 = 0.8 μM.	30268702
PBMC	Antiinflammatory assay			Antiinflammatory activity against human PBMC cells assessed as LPS-induced IL-6 production by chemiluminescence assay, IC50 = 0.31623 μM.	24015967
Rosetta2 DE3	Function assay			Binding affinity to biotinylated BRD3 BD2 (306 to 417 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.0407 μM.	26080064
Rosetta2 DE3	Function assay			Binding affinity to biotinylated BRD2 BD2 (349 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.0454 μM.	26080064
Rosetta2 DE3	Function assay			Binding affinity to biotinylated BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.0476 μM.	26080064
Rosetta2 DE3	Function assay			Binding affinity to biotinylated BRD3 BD1 (24 to 144 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.0607 μM.	26080064
Rosetta2 DE3	Function assay			Binding affinity to biotinylated BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.0994 μM.	26080064
Rosetta2 DE3	Function assay			Binding affinity to biotinylated BRD2 BD1 (72 to 205 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.159 μM.	26080064
BL21(DE3)	Function assay			Binding affinity to N-terminal His6-tagged-BRD4 bromodomain 2 (unknown origin) expressed in competent Escherichia coli BL21(DE3) cells by isothermal titration calorimetry, Kd = 0.065 μM.	26367539
BL21(DE3)	Function assay			Binding affinity to N-terminal His6-tagged-BRD4 bromodomain 1 (unknown origin) expressed in competent Escherichia coli BL21(DE3) cells by isothermal titration calorimetry, Kd = 0.095 μM.	26367539
BL21(DE3)	Function assay			Binding affinity to full length N-terminal His6-tagged-BRD2 bromodomain 2 (unknown origin) expressed in competent Escherichia coli BL21(DE3) cells by isothermal titration calorimetry, Kd = 0.1 μM.	26367539
BL21(DE3)	Function assay			Binding affinity to full length N-terminal His6-tagged-BRD2 bromodomain 1 (unknown origin) expressed in competent Escherichia coli BL21(DE3) cells by isothermal titration calorimetry, Kd = 0.23 μM.	26367539
BL21(DE3)-R3-pRARE2	Function assay			Inhibition of human His-tagged BRD4 bromodomain 2 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by FRET assay, IC50 = 0.036 μM.	26731490
BL21(DE3)-R3-pRARE2	Function assay			Inhibition of human His-tagged BRD4 bromodomain 1 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by FRET assay, IC50 = 0.036 μM.	26731490
THP1	Antiproliferative assay			Antiproliferative activity against human THP1 cells, IC50 = 0.29 μM.	28939121
TY82	Antiproliferative assay			Antiproliferative activity against human TY82 cells, IC50 = 0.39 μM.	28939121
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
Saos-2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	29435139
NB1643	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
HL60	Cytotoxicity assay			Cytotoxicity against human HL60 cells by MTS assay, IC50 = 0.12 μM.	29657099
Raji	Function assay			Inhibition of BRD4-BD1 in human Raji cells assessed as downregulation of MYC gene expression by PCR method, IC50 = 0.132 μM.	29657099
LNCAP	Antiproliferative assay			Antiproliferative activity against human LNCAP cells, IC50 = 0.3565 μM.	29758518
點擊查看更多細胞系數據

生物活性

產品描述

靶點

BET proteins ^[1]
(Cell-free assay)

35 nM

體外研究(In Vitro)
體外研究活性	I-BET-762抑制BET(溴區(qū)和額外的末端結構域) 蛋白, BRD2, BRD3 和 BRD4, 結合到BET的串聯(lián)溴區(qū)，K_d為50.5-61.3 nM, 在FRET分析中，置換BET串聯(lián)溴區(qū)的一種四乙酰化的H4肽，IC50為32.5-42.5 nM。I-BET-762占據BET蛋白的乙酰基-賴氨酸結合口袋，并抑制BET蛋白結合到乙?；慕M蛋白，從而破壞了炎性基因表達必不可少的染色質復合物的形成。^[1]分化過程中的第2天使用I-BET-762處理，改變CD4⁺T細胞的細胞因子產生，上調一些抗炎基因產物的表達，并下調一些促炎細胞因子的表達。^[2]
激酶實驗	熒光共振能量轉移（FRET）滴定
激酶實驗	在有四乙酰化的組蛋白H4肽（200 nM）存在時，在50 mM HEPES pH7.5, 50 mM NaCl, 0.5 mM CHAPS中進行對BRD2 (200 nM), BRD3 (100 nM) 和 BRD4 (50 nM)的I-BET滴定。平衡1小時后，在含0.05% (v/v) BSA 和 400 mM KF的實驗緩沖液中加入2nM 銪穴狀化合物標記的鏈霉親和素和10 nM XL-665標記的anti-6His 抗體，使用FRET檢測溴區(qū)蛋白：肽相互作用。使用Envision酶標儀（激發(fā)菠菜320 nm，發(fā)射波長615 nm和665 nm）對實驗板進行讀數。
細胞實驗	細胞系	CD4⁺ T 細胞
	濃度	~500 nM
	孵育時間	60-72 小時
	方法	從10到12周的小鼠淋巴結和脾中分離CD4⁺ T細胞，在指定細胞因子存在時，使用與板結合的anti-CD3和anti-CD28抗體活化。在最初激活的60-72小時，包含I-BET-762化合物。在T細胞培養(yǎng)和擴張的5天過程中，化合物稀釋到初始濃度的12倍。
實驗圖片	檢測方法	檢測指標	實驗圖片	PMID
實驗圖片	Growth inhibition assay	Cell viability		26840085

體內研究(In Vivo)
體內研究活性	I-BET-762保護防止脂多糖誘導的內毒素休克和細菌誘導的膿毒病。LPS注射后1.5小時，單劑量I-BET處理，可治愈小鼠。I-BET每日兩次注射，持續(xù)2天，保護小鼠免于膿毒癥引起的死亡。^[1]早期I-BET-762處理實驗性自身免疫性腦脊髓炎（EAE）小鼠模型，抑制Th1分化的2D2 T細胞誘發(fā)神經性炎癥的能力。^[2]
動物實驗	Animal Models	小鼠
	Dosages	30 mg/kg
	Administration	靜脈注射

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試驗信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT03266159	Withdrawn	Solid Tumours	GlaxoSmithKline	November 27 2017	Phase 2
NCT02964507	Terminated	Neoplasms	GlaxoSmithKline	February 2 2017	Phase 1
NCT01943851	Completed	Neoplasms	GlaxoSmithKline	May 14 2014	Phase 2
NCT01587703	Completed	Carcinoma Midline	GlaxoSmithKline	March 28 2012	Phase 1

參考文獻
[1] Nicodeme E, et al. Nature, 2010, 468(7327), 1119-1123. [2] Bandukwala HS, et al. PNAS, 2012, 109(36), 14532-14537.

參考文獻

[1] Nicodeme E, et al. Nature, 2010, 468(7327), 1119-1123.
[2] Bandukwala HS, et al. PNAS, 2012, 109(36), 14532-14537.

化學信息&溶解度

分子量	423.9	分子式	C₂₂H₂₂ClN₅O₂
CAS號	1260907-17-2	SDF	Download Molibresib (I-BET-762) SDF
Smiles	CCNC(=O)CC1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C
儲存條件(自收到貨起)	3年-20°C粉狀	儲備液保存和期限建議分裝儲備液，避免反復凍融！	1年-80°C溶于溶劑
儲存條件(自收到貨起)	3年-20°C粉狀	儲備液保存和期限建議分裝儲備液，避免反復凍融！	1個月-20°C溶于溶劑

體外溶解度
批次：

DMSO : 84 mg/mL ( (198.15 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Ethanol : 42 mg/mL (99.07 mM)

Water : Insoluble

DMSO : 85 mg/mL ( (200.51 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Ethanol : 43 mg/mL (101.43 mM)

Water : Insoluble

DMSO : 84 mg/mL ( (198.15 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Ethanol : 42 mg/mL (99.07 mM)

Water : Insoluble

摩爾濃度計算器

體內溶解配方批次：現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑				動物體內配方計算器
均勻懸濁液	CMC-NA	5mg/ml (11.80mM)	均勻懸濁液可用于口服和腹腔注射。以 1 mL 工作液為例，取 5 mg該產品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。
均勻懸濁液	CMC-NA	5mg/ml (11.80mM)	均勻懸濁液可用于口服和腹腔注射。以 1 mL 工作液為例，取 5 mg該產品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。
澄清溶液	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O 該配方已經過Selleck實驗室實測。如果上述溶解方案不能滿足您的需求，可聯(lián)系Selleck銷售提供定制化測試。	4.250mg/ml (10.03mM)	以 1 mL 工作液為例，取50μL85mg/ml的澄清DMSO儲備液加到400μL PEG300中，混合均勻使其澄清；向上述體系中加入50μLTween80，混合均勻使其澄清；然后繼續(xù)加入500μL ddH2O定容至 1 mL。工作液請現(xiàn)配現(xiàn)用！
均勻懸濁液	CMC-NA	5mg/ml (11.80mM)	均勻懸濁液可用于口服和腹腔注射。以 1 mL 工作液為例，取 5 mg該產品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。

實驗計算

摩爾濃度計算器

質量	濃度	體積	分子量
=	×	×

稀釋計算器分子量計算器

動物體內配方計算器（澄清溶液）

第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）

給藥劑量 mg/kg 動物平均體重 g 每只動物給藥體積 μL 動物數量只

第二步：請輸入動物體內配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

計算結果：

工作液濃度： mg/ml；

DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；

體內配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH₂O，混勻澄清。

體內配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。

注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。

技術支持

在訂購、運輸、儲存和使用我們的產品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時內盡快聯(lián)系您。

操作手冊

如果有其他問題，請給我們留言。

* 必填項

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Molibresib (I-BET-762)

產品質控

Molibresib (I-BET-762)相關產品

相關信號通路圖

細胞實驗數據示例

生物活性

化學信息&溶解度

實驗計算

技術支持